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Abstract
Acromegaly is a rare disease with nonspecific symptoms with acral enlargement being
almost universally present at diagnosis. The estimated prevalence is 40–125 cases/million
but targeted universal screening studies have found a higher prevalence (about 10 fold).
The aim of the ACROSAHS study was to investigate the prevalence of acromegaly and
acromegaly comorbidities in patients with sleep apnea symptoms and acral enlargement.
ACROSAHS was a Spanish prospective non-interventional epidemiological study in 13 Hos-
pital sleep referral units. Facial and acral enlargement symptoms including: ring size and
shoe size increase, tongue, lips and jaws enlargement, paresthesia or carpal tunnel syn-
drome and widening of tooth spaces, as well as other typical acromegaly comorbidities were
recorded with a self-administered questionnaire of patients who attended a first visit for
sleep apnea symptoms between 09/2013 and 07/2014. Serum insulin-like growth factor
type 1 (IGF1) was measured in patients with1 acral symptom to determine the prevalence
of acromegaly. Of the 1557 patients enrolled, 1477 with complete data (72% male) were
analyzed. 530 patients (36%) reported at least 1 acral enlargement symptom and were
tested for IGF-1, 41 were above range, persisted in 7, and among those, 2 cases of acro-
megaly were diagnosed (prevalence of at least 1.35 cases/1000). Overall, 1019 patients
(69%) had2 acromegaly symptoms and should have been screened according to guide-
lines; moreover 373 patients (25%) had1 symptom of acral enlargement plus3 other
acromegaly symptoms. In conclusion, in patients with sleep apnea symptoms and acral
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enlargement, we found an acromegaly prevalence of at least 1.35 cases per 1000 and a
high prevalence of typical acromegaly symptoms. It is important that sleep specialists are
aware of acromegaly symptoms to aid with acromegaly diagnosis.
Introduction
Acromegaly is a rare disease resulting from overproduction of growth hormone (GH) by the
pituitary, mostly from a GH-producing adenoma [1]. It is an insidious condition that usually
takes years of symptoms before a correct diagnosis, partly due to the high population preva-
lence of comorbidities associated with the disease and the low awareness of the condition. It is
estimated that the diagnosis is delayed between 6 and 20 years after the appearance of the first
symptom [2] and is thought to be under-recognized and under-diagnosed [3].
The estimated prevalence is 40 to 125 cases per million according to different epidemiologi-
cal studies [4–8], but recent population based studies have shown that prevalence could be 5 to
15 times higher [9–13]. Schneider et al, in an unselected German population from a primary
care center, found a prevalence of 1000 cases per million (1/1000) [9]. Rosario et al, in a Brazil-
ian primary care population selected for symptoms of increased ring size or shoe size found a
prevalence of 365 per million (0.365/1000) [10]. Rosario et al, in a selected population of
patients with type 2 diabetes, found a prevalence of 480 cases per million (0.48/1000) [11]. The
same authors showed that the probability of acromegaly in a hypertensive population without
acral enlargement was very unlikely [12]. Recently, Galerneau et al described the prevalence of
acromegaly in unselected patients with suspected sleep apnea-hypopnea syndrome (SAHS)
and fount it to be 2.5/1000 [13].
Facial and acral enlargement is the most common symptom of the disease (70–80%), and it
is highly prevalent at diagnosis [3,14,15]. Respiratory problems are major comorbidities
responsible for 25% of the mortality in these patients [16]. SAHS has been reported in about
88% of patients with acromegaly (both active and inactive) [17,18] due to anatomical changes
in bone structures and soft tissue enlargement of the upper airway [18]. These changes lead to
snoring as a characteristic symptom of the disease.
Since there are not pathognomonic clinical features that allow for an early diagnosis, the
American Association of Clinical Endocrinologists (AACE) guidelines [19] recommend
(Grade A evidence) actively searching for the disease in patients with at least two of the follow-
ing signs or symptoms: abnormal acral enlargement (hands, feet, facial changes) hypertension,
diabetes, joint pain, fatigue, cardiac disorders including ventricular hypertrophy and systolic
or diastolic dysfunction, headaches, carpal tunnel syndrome, sleep apnea syndrome, sweating,
loss of vision, colonic polyps, and progressive mandibular malocclusion [19,20]. In recent
guidelines [21], Katznelson et al recommended measuring insulin-like growth factor 1 (IGF-1)
in patients who have several of these associated conditions: sleep apnea syndrome, type 2 dia-
betes mellitus, debilitating arthritis, carpal tunnel syndrome, hyperhidrosis, and hypertension.
The prevalence of acromegaly in patients presenting sleep apnea symptoms has only been
reported in one recent French study [13].
The aim of the present study was to investigate acromegaly prevalence in patients who are
referred to sleep units for suspected sleep apnea syndrome and who also have symptoms of
facial and acral enlargement. The secondary aim was to study the prevalence of typical acro-
megaly symptoms and comorbidities in order to estimate what proportion of patients should
be screened according to current consensus guidelines. We also compared symptom preva-
lence between patients with persistently elevated IGF 1 and patients without elevated IGF-1.
Acromegaly in sleep apnea
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Patients and methods
This was an investigator initiated, multicenter, prospective epidemiological study, involving 13
Spanish hospitals. The protocol was reviewed and approved by the reference Ethics Committee
as well as the local Ethics Committees. Signed informed consent was obtained from all patients
and the reported investigations were carried out in accordance with the principles of the Dec-
laration of Helsinki as revised in 2008.
New patients seen between September 2013 and July 2014 in the sleep referral units of the
participating centers were offered to enter the study. To participate, patients had to have snor-
ing or suspected SAHS, be over 18 years of age, and sign the informed consent. Exclusion crite-
ria included: uncontrolled gastrointestinal or malabsorptive disease, pregnancy, severe liver or
kidney disease (glomerular filtration rate [GFR] <30), and active cancer.
Patients followed the usual protocol evaluation for suspected SAHS at each referral unit
and had a polysomnography (PSG) or conventional polygraphy when indicated. Test results as
well as the apnea-hypopnea index (AHI) (number of apnea/hypopnea events per hour of
recording), were collected in addition to the reasons for referral to the sleep unit. Enrolled
patients underwent a complete physical examination including blood pressure, weight and
height, and measurement of ring finger circumference and length (fourth finger of the non-
dominant hand).
A self-administered questionnaire of symptoms and comorbidities typically found in acro-
megaly was provided to patients and was later discussed with the attending physician to resolve
or clarify any possible doubts. Collected symptoms were divided in two groups: 1: those related
to facial and acral enlargement: increased ring size, increased shoe size, lips or jaw enlarge-
ment, tooth space widening, tongue enlargement, paresthesia in hands or carpal tunnel syn-
drome and 2: other typical acromegaly symptoms and comorbidities including: headaches,
hoarse voice, arthralgia, menstrual disturbances in women, erectile dysfunction in men, diabe-
tes, high blood pressure, fatigue, and excessive perspiration. Patients who presented any symp-
tom of the acral enlargement group underwent a blood draw for serum IGF-1 testing.
IGF-1 was determined at each center’s local laboratory. If the IGF-1 values were elevated, a
second sample was obtained to repeat the analysis. In patients with re-confirmed supranormal
IGF-1 (>2 standard deviations [SD] adjusted for age and sex), an oral glucose tolerance test
(OGTT) with GH measurements was performed. GH was measured also at each of the collabo-
rating centers. Nadir GH >0.4 ng/mL was considered abnormal. In patients with no GH sup-
pression or high suspicion of acromegaly, a pituitary magnetic resonance imaging (MRI) was
obtained.
Mean and standard deviation are reported for continuous variables, and number and per-
centage are reported for categorical variables. The statistical analysis was performed using R
v3.02. The potential relationship between the response variable (presence of acromegaly and/
or persistent IGF-1) and the explanatory variables (all collected secondary variables) was
examined by means of bivariate analyses, applying the following methods: Chi-Square test,
Fisher exact test or LR Chi-Square test for qualitative variables and Analysis of Variance or
Kruskal-Wallis test for quantitative variables. The compliance of application conditions was
performed using Shapiro-Wilk and Kolmogorov-Smirnov normality tests and Levene tests for
homogeneity of variances. For all statistical tests a nominal significance level of 5% (P <0.05)
was applied.
Results
A total of 1557 patients were enrolled in the study. Eighty patients were excluded due to proto-
col violations (mainly presence of acral enlargement without IGF-1 results). A total of 1477
Acromegaly in sleep apnea
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patients were analyzed, and their patient characteristics and demographic data are shown in
Table 1.
Reasons for being referred to the sleep unit were: snoring (46%), day-time sleepiness (32%)
and/or apnea-hypopnea (55%). Eighty-eight percent of patients (n = 1306) had available results
for specific SAHS tests: polysomnography (37%) or conventional polygraphy (63%). Ninety-
four percent of them were confirmed to have SAHS.
Acromegaly prevalence
A total of 530 patients had IGF-1 measured and 41 were above the age- and sex-adjusted refer-
ence range. IGF-1 elevation in a second sample was reconfirmed in 7 patients. Only one of
them had all pre-specified criteria for acromegaly diagnosis: IGF-1 persistently elevated, GH
nadir >0.4 ng/mL and a pituitary microadenoma. A second patient with persistently high
IGF-1 (2.8 times the upper limit of normal [ULN] of the gender and age range) had GH sup-
pression on the OGTT (0.31 ng/mL) but presented a florid symptomatic acromegaly. Pituitary
MRI showed a microadenoma. In both cases the tumor was removed and histologically proved
with the subsequent IGF-1 normalization and amelioration of symptoms. Therefore, we found
2 proven cases of acromegaly in our cohort, which represents an acromegaly prevalence of at
least 1354 cases per million (1.35/1000).
The other five cases of patients with persistently elevated IGF-1 (between 1.13 and 1.57 x
ULN) had GH suppression on the OGTT (below 0.4 ng/mL). One of them had a 2.8 mm
microadenoma on the MRI. All patients with persistently elevated IGF-1 are being followed.
Acromegaly symptom prevalence
Acral enlargement prevalence is shown in Table 2. A total of 530 patients (35.9%) reported at
least one acral enlargement symptom: 226 (15.3%) had 1, 159 (10.8%) had 2 and 145 (9.8%)
had3 symptoms (Fig 1). The most common was paresthesia in hands (25.7%) followed by
increase in ring size (17.6%) and increase in shoe size (10.8%).
Prevalence of other typical acromegaly symptoms and comorbidities are shown in Table 2.
Only 222 patients (15.0%) did not report to have any acromegaly symptoms or comorbidities,
236 (16.0%) reported 1, 310 (21.0%) 2 and 709 (48.0%)3 acromegaly symptoms or comor-
bidities (Fig 1). The mean number of acromegaly symptoms and comorbidities in the whole
cohort was 2.5 ± 1.75. Moreover, a total of 373 patients (25.3%) had1 acral symptom and3
other acromegaly symptoms.
Table 1. Patient demographics (N = 1477).
Age (years) 55.6 ± 12.4
Sex: male/female (n, %) 1064, 72%/413, 28%
Weight (Kg) 90.2 ± 18.9
Height (cm) 169 ± 9.7
BMI 31.7 ± 6.3
Waist (cm) 108 ±15
SBP (mmHg) 133 ±18.7
DBP (mmHg) 79.9 ±13.7
BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure. Results are mean ± SD
or % when indicated
https://doi.org/10.1371/journal.pone.0183539.t001
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Clinical differences between patients with acromegaly and the rest
We compared the clinical characteristics of the patients with confirmed acromegaly (n = 2)
with the rest. (n = 1475).
Apnea-hypopnea index (AHI) was significantly higher in patients with acromegaly: 81
(range: 72–90) vs 33 events per hour (range 18–52) (p = 0.045). Patients with acromegaly had a
higher prevalence of hoarse voice (100% vs 19%). Moreover both patients with acromegaly
had acral enlargement symptoms (100% vs 41%) and3 other acromegaly symptoms (100%
vs 60.5%). The total number of acral symptoms was 1.5 ± 1.1 in patients versus 0.71 ± 1.1
(p = ns). The total number of other acromegaly symptoms was 4.0 ± 1.4 in patients versus
2.5 ± 1.7 (p = ns).
Clinical characteristics of patients with persistently elevated IGF-1
We analyzed the clinical characteristics of the 7 patients with persistently elevated IGF-1 (5
without a confirmed diagnosis of acromegaly and 2 with confirmed diagnosis) and compared
them with the rest of the patients (n = 1470). Clinical characteristics are shown in Table 3.
Symptom rates are shown in Fig 2. There was a higher prevalence of shoe size increase: (43%
vs 11%; p = 0.027) paresthesia (71% vs 28%; p = 0.023), hoarse voice (57 vs 18%; p = 0.021)
arthralgia (100% vs 47%; p = 0.005) and diabetes (71% vs 15%; p = 0.001) in patients with per-
sistently elevated IGF-1. The total number of acral symptoms was 1.7 ± 0.9 versus 0.7 ± 1.1
(p = 0.03) and the total number of other acromegaly symptoms was 4.6 ± 0.9 versus 2.5 ± 1.7
(p = 0.001). Of note, all 7 patients (100%) had acral symptoms plus3 acromegaly symptoms
compared with 25% of the rest of the patients.
Discussion
In the present study we have found a prevalence of acromegaly that was higher than expected
in patients consulting to sleep referral units for sleep apnea symptoms and/or snoring that also
had acral growth symptoms. The prevalence of1.35 in 1000 cases is higher than what is
Table 2. Acromegaly symptoms in the whole cohort.
Acral enlargement symptoms N = 1477
n (%)
Increased ring size 260 (17.6)
Increased shoe size 159 (10.8)
Lips or jaw enlargement 87 (5.9)
Tooth space widening 112 (7.6)
Tongue enlargement 55 (3.7)
Paresthesia in hands 380 (25.7)
Other typical acromegaly symptoms
Headaches 355 (24.0)
Hoarse voice 261 (17.7)
Arthralgia 706 (47.6)
Menstrual disturbances (n = 273) 61 (4.1)
Erectile dysfunction (n = 930) 237 (16.0)
Diabetes 226 (15.3)
High blood pressure 630 (42.7)
Fatigue 810 (54.8)
Excessive perspiration 442 (29.9)
https://doi.org/10.1371/journal.pone.0183539.t002
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estimated in the general population (0.04–0.12/1000) and it is closer to the prevalence reported
by Schneider in an unselected population from primary care units (1/1000) [4–12] but lower
than the prevalence recently reported by Galerneau et al in a non-selected population of patients
with suspected SAHS (2.5/1000) [13]. In addition, our study reported a high prevalence of typi-
cal acromegaly symptoms and co-morbidities in the studied population: 36% of participants
experienced symptoms of acral enlargement, with paresthesia being the most common acral
symptom (29%), 69% had2 other typical acromegaly symptoms and 48% had3.
We found an acromegaly prevalence of at least 1.35 cases per 1000. In calculating this figure
we have assumed that there were no cases in the group who did not refer acral changes, but we
cannot exclude the possibility of acromegaly in that group. Moreover, we have not included
the 5 patients with persistently elevated IGF-1 with GH suppression in the OGTT. Although
we cannot completely rule out acromegaly in those 5 cases, all IGF-1 elevations were mild and
there was no tumor in 4 of the patients and the physicians who cared for those patients decided
Fig 1. Number of acromegaly symptoms. Bars represent percent of patients with different number of
acromegaly symptoms. Acral: acral enlargement symptoms. Other: other acromegaly symptoms.
https://doi.org/10.1371/journal.pone.0183539.g001
Table 3. Clinical and biochemical characteristics of the 7 patients with persistently elevated IGF1.
IGF1 Repeated IGF1 Mean IGF1 ULN GH nadir IGF1 x ULN Sex Age MRI Sizea
(mm)
268 238 253 185 0.16 1.37 M 55 microadenoma 2.8
240 226 233 185 0.37 1.26 M 66 normal
292 219 255.5 163 0.23 1.57 M 48 normal
271 315 293 242 0.29 1.21 F 59 normal
202 217 209.5 185 0.38 1.13 M 55 normal
Confirmed acromegaly
262 260 261 231 1.5 1.13 M 65 microadenoma 9
491 567 529 200 0.31 2.65 F 67 microadenoma 5
aSize: maximum diameter.
IGF1 and GH are in ng/mL. F, female; GH, growth hormone; IGF1, insulin-like growth factor 1; M, male; MRI, magnetic resonance imaging; ULN, upper limit
of normal.
https://doi.org/10.1371/journal.pone.0183539.t003
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to follow-up on them with no specific treatment. In the selected population of patients with
suspected SAHS, acromegaly prevalence is at least 10 to 20 times higher than what is assumed
for the general population [4–8].
Of note, one of the acromegaly cases, despite having a clearly elevated IGF-1 (2.8 x ULN),
had GH suppression by glucose (nadir GH: 0.31 ng/mL). The patient also had diabetes and
grade II obesity (BMI = 35). Several investigators have reported that acromegaly may be pres-
ent despite GH suppression on the OGTT [22–25]. Dimaraki et al, found that 50% of acromeg-
aly cases occurred with GH suppression in a series of patients referred to a specialized unit, for
reasons including discrepancies in diagnostic tests [22]; however, they estimated that in the
general acromegaly population, that figure is probably close to 25%. Freda hypothesized that
the discrepancies may depend on the GH assay used and the cut-off considered [25]. In
explaining discrepancies, we have to account that 85% of somatotropinomas are macroadeno-
mas; it is possible that microtumors could still respond to glucose, similar to what happens in
other endocrine adenomas (parathyroid adenomas responding to calcium or adrenocortico-
tropic hormone producing tumors responding to high doses of dexamethasone). In the present
study, the patient with GH suppression on the OGTT had a small microtumor only seen in the
3-tesla pituitary MRI (5 mm maximum diameter).
Remarkably, patients with persistently elevated IGF-1 had a higher prevalence of typical
acromegaly symptoms and comorbidities (100% had3), and the number of acral as well as
other acromegaly symptoms was significantly higher than in the rest of population studied.
We cannot completely rule out acromegaly in the group of patients with persistently elevated
IGF-1, even though 4 of 5 patients had a normal MRI (and one had a normal octreoscan to
rule out an ectopic source), but there have been described acromegaly cases without a visible
adenoma in the MRI [26]. If the 5 cases with persistently elevated IGF-1 in our study had been
considered as having acromegaly, we would be facing a very high prevalence of the disease in
this particular population.
Similar to our results, Galerneau et al found 6 patients with persistently elevated IGF-1 and
normal GH on the OGTT in a cohort of 817 patients with suspected SAHS [13].
In patients with elevated IGF-1 levels and normal GH suppression, one should also con-
sider accuracy of the IGF-1 measurement. It is known that different IGF-1 assays perform
Fig 2. Prevalence of acromegaly symptoms. (A) acral enlargement and (B) other acromegaly symptoms in patients with persistently elevated IGF-1
(n = 7, light grey) and the rest of patients (n = 1470, dark grey). *p>0.05.
https://doi.org/10.1371/journal.pone.0183539.g002
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differently and that in a UK study, the diagnosis of acromegaly was inaccurately excluded in
30% of single samples assayed for IGF-1 in 23 different laboratories [27]. In our study, there
were 34 patients with a high IGF-1 value that was not reconfirmed in a second sample. Since
this was a screening study, each of the 13 centers used their standard IGF-1 assay in order to
reproduce “real life” screening conditions.
We found a high prevalence of typical acromegaly symptoms in the studied population.
According to AACE guidelines, 69% of the patients (who had2 typical acromegaly symptoms
or comorbidities) should have undergone a screen test for acromegaly [19]. This result is very
similar to what has been recently reported by Galerneau et al [13]. Current guidelines suggest
screening if several acromegaly symptoms are present [21]; therefore, a high number of patients
who consult to rule out sleep apnea syndrome would need an IGF-1 test to rule out GH excess.
Since acral enlargement is almost universally present in acromegaly [3,14,15], recognizing acral
enlargement features would lower the population requiring screening to 36%. We believe that it
is necessary to train specialists who care for these patients on the importance of recognizing
acral enlargement features. Moreover, the two acromegaly cases (as well as the other 5 patients
with persistently high IGF-1), had at least one acral symptom and three or more other typical
acromegaly symptoms. A 25.5% of the studied population met those criteria; we believe at least
that subgroup should be screened. Economic studies to prove cost-effectiveness are warranted.
Since symptoms attributed to SAHS may improve with SAHS treatment, it may be interesting
to see if after treatment, the population to be screened narrows down.
Acromegaly symptoms, even acral enlargement, are non-specific. Patients with SAHS are
usually overweight or obese [28], mean BMI of the cohort was in the obesity range -31.6 kg/
m2-, it is possible that obesity played a confounding role in the evaluation of symptoms in this
patient cohort. Regarding physiopathology, acromegaly may cause sleep apnea due to facial
anatomical changes and soft tissue enlargement [18]. The prevalence of SAHS in patients with
acromegaly is very high according to several studies (60–88%) [17–18, 29]. Acromegaly causes
macroglosia and upper airway narrowing due to laryngeal soft tissue enlargement [18].
Among the different cephalometric measurements taken on the MRI, enlarged soft palate,
uvula and tongue are considered directly related to SAHS pathogenesis [18, 30]. Treatment of
acromegaly both with somatostatin analogs and pegvisomant has been shown to improve
SAHS severity but there are variable responses and up to 40–50% of controlled patients may
still have SAHS [31, 32]. An early diagnosis of the disease may help in avoiding comorbidities.
Limitations to this study have to be acknowledged. Even though acral enlargement is almost
universally present at diagnosis in acromegaly [3,14,15], it is known that sometimes patients
do not recognize slow developing symptoms on themselves. This could have underestimated
our results; however, the prevalence of acromegaly in our study would still be at least 1.35/
1000. One could also argue that the 5 cases with persistently elevated IGF-1, particularly the
one with a pituitary microadenoma are in fact, acromegaly cases. We did not include them in
the acromegaly group because we did not have pathological certainty of an acromegaly diagno-
sis and the findings could have been related to the IGF-1 assay. However, patients with persis-
tently elevated IGF-1 clearly had a high prevalence of several acromegaly symptoms and
comorbidities. At the moment, we have chosen to be cautious and are closely following these 5
patients before making a specific diagnosis.
Conclusions
In conclusion, we have found an acromegaly prevalence of at least 1.35 cases per 1000 in a pop-
ulation of patients with sleep apnea symptoms and acral enlargement who consult to a sleep
specialist. We have also found a very high prevalence of typical acromegaly symptoms in this
Acromegaly in sleep apnea
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cohort. It is important that sleep specialists are aware of the disease and recognize its symp-
toms, particularly those related to facial and acral enlargement, in order to perform an early
diagnosis.
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